New drug TL-003 enters first human tests for ulcerative colitis
NCT ID NCT07526519
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug, TL-003, for the first time in humans. The main goal is to check its safety and how the body processes it in 48 healthy adults, with a small group of people who have ulcerative colitis also being studied. Researchers will monitor for side effects and measure drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TL-003
- What this could lead to
- If successful, this could pave the way for larger studies testing TL-003 as a potential treatment for ulcerative colitis.
- What could go wrong
- This is a very early Phase 1 trial with only 48 participants, focused on safety, not effectiveness. The drug may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Linear Early Phase Ltd
RECRUITINGPerth, Western Australia, 6009, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?